All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Luspatercept granted FDA approval as a first-line treatment for anemia in patients with lower-risk MDS

Aug 29, 2023
Learning objective: After reading this article, learners will be able to cite a new development in lower-risk MDS.

On August 28, luspatercept-aamt, a first-in-class erythroid-maturation agent, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of anemia in erythropoiesis-stimulating agent (ESA)-naïve, adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require red blood cell (RBC) transfusions.1

Luspatercept-aamt was granted priority review by the FDA for the same indication, and was previously approved by the FDA and the European Medicines Agency (EMA) for the treatment of anemia in patients with MDS with ring sideroblasts who are transfusion-dependent and do not respond to or are ineligible for ESA treatment.

This approval is based on interim results from the open-label, randomized, phase III COMMANDS trial (NCT03682536), covered here on the MDS Hub, that found luspatercept-aamt to be associated with improved RBC transfusion independence and increased hemoglobin when compared with epoetin alfa, independent of ring sideroblast status, in patients with lower-risk MDS who are RBC transfusion-dependent and ESA-naïve.1

  1. Bristol Myers Squibb. S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes (MDS) who may require transfusions. Published Aug 28, 2023. Accessed Aug 29, 2023.


Subscribe to get the best content related to MDS delivered to your inbox